Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.49% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 411.33M.
Undervalued
The company’s latest PE is 3.01, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 80.96M shares, decreasing 5.11% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 154.99K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.24.